Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Kim Chi, Nicola Jane Lawrence et al.|The Lancet Oncology|2023Cited by 195
A comparison of <scp>DNA</scp> sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryAtara Posner, Richard W. Tothill, Owen W.J. Prall et al.|The Journal of Pathology|2022Cited by 27